These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35058605)

  • 1. Effects of a low free sugar diet on the management of nonalcoholic fatty liver disease: a randomized clinical trial.
    Khodami B; Hatami B; Yari Z; Alavian SM; Sadeghi A; Varkaneh HK; Santos HO; Hekmatdoost A
    Eur J Clin Nutr; 2022 Jul; 76(7):987-994. PubMed ID: 35058605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of a low fructose and low glycemic index/load (FRAGILE) dietary intervention on indices of liver function, cardiometabolic risk factors, and body composition in children and adolescents with nonalcoholic fatty liver disease (NAFLD).
    Mager DR; Iñiguez IR; Gilmour S; Yap J
    JPEN J Parenter Enteral Nutr; 2015 Jan; 39(1):73-84. PubMed ID: 23976771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of a fruit-rich diet on liver biomarkers, insulin resistance, and lipid profile in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
    Alami F; Alizadeh M; Shateri K
    Scand J Gastroenterol; 2022 Oct; 57(10):1238-1249. PubMed ID: 35710164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial.
    Schwimmer JB; Ugalde-Nicalo P; Welsh JA; Angeles JE; Cordero M; Harlow KE; Alazraki A; Durelle J; Knight-Scott J; Newton KP; Cleeton R; Knott C; Konomi J; Middleton MS; Travers C; Sirlin CB; Hernandez A; Sekkarie A; McCracken C; Vos MB
    JAMA; 2019 Jan; 321(3):256-265. PubMed ID: 30667502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross-sectional study.
    Tutunchi H; Naeini F; Ebrahimi-Mameghani M; Mobasseri M; Naghshi S; Ostadrahimi A
    Int J Clin Pract; 2021 Jun; 75(6):e14131. PubMed ID: 33683797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.
    Namkhah Z; Naeini F; Mahdi Rezayat S; Mehdi Yaseri ; Mansouri S; Javad Hosseinzadeh-Attar M
    Int J Clin Pract; 2021 Nov; 75(11):e14852. PubMed ID: 34516703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial.
    Jazayeri-Tehrani SA; Rezayat SM; Mansouri S; Qorbani M; Alavian SM; Daneshi-Maskooni M; Hosseinzadeh-Attar MJ
    Nutr Metab (Lond); 2019; 16():8. PubMed ID: 30705687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial.
    Moradi F; Kooshki F; Nokhostin F; Khoshbaten M; Bazyar H; Pourghassem Gargari B
    J Trace Elem Med Biol; 2021 Jan; 63():126659. PubMed ID: 33045675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of sumac (Rhus coriaria L.) powder supplementation in patients with non-alcoholic fatty liver disease: A randomized controlled trial.
    Kazemi S; Shidfar F; Ehsani S; Adibi P; Janani L; Eslami O
    Complement Ther Clin Pract; 2020 Nov; 41():101259. PubMed ID: 33190008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Electroacupuncture combined with lifestyle control on obese nonalcoholic fatty liver disease: a randomized controlled trial].
    Dong C; Zhang CR; Xue BY; Miu WF; Fang NY; Li K; Ou ZJ; Xu YQ
    Zhongguo Zhen Jiu; 2020 Feb; 40(2):129-34. PubMed ID: 32100496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary fructose intake in obese children and adolescents: relation to procollagen type III N-terminal peptide (P3NP) and non-alcoholic fatty liver disease.
    Hamza RT; Ahmed AY; Rezk DG; Hamed AI
    J Pediatr Endocrinol Metab; 2016 Dec; 29(12):1345-1352. PubMed ID: 27442361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D and nonalcoholic fatty liver disease in children: a randomized controlled clinical trial.
    El Amrousy D; Abdelhai D; Shawky D
    Eur J Pediatr; 2022 Feb; 181(2):579-586. PubMed ID: 34459959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial.
    Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    BMC Complement Altern Med; 2019 Mar; 19(1):59. PubMed ID: 30871514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of different insulin resistance indices in assessment of non-alcoholic fatty liver disease in overweight/obese children.
    El-Karaksy HM; El-Raziky MS; Fouad HM; Anwar GM; El-Mougy FM; El-Koofy NM; El-Hennawy AM
    Diabetes Metab Syndr; 2015; 9(2):114-9. PubMed ID: 25470627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
    Zhou ST; Cui W; Kong L; Yang X
    Curr Med Sci; 2022 Jun; 42(3):513-519. PubMed ID: 35451807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 17. Glucose homeostasis, insulin resistance and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Beneficial effects of supplementation with microalgae Chlorella vulgaris: A double-blind placebo-controlled randomized clinical trial.
    Ebrahimi-Mameghani M; Sadeghi Z; Abbasalizad Farhangi M; Vaghef-Mehrabany E; Aliashrafi S
    Clin Nutr; 2017 Aug; 36(4):1001-1006. PubMed ID: 27475283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fructose as a key player in the development of fatty liver disease.
    Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
    Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
    Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of time-restricted feeding (16/8) combined with a low-sugar diet on the management of non-alcoholic fatty liver disease: A randomized controlled trial.
    Kord-Varkaneh H; Salehi-Sahlabadi A; Tinsley GM; Santos HO; Hekmatdoost A
    Nutrition; 2023 Jan; 105():111847. PubMed ID: 36257081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.